Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lumakras
Biotech
Roche orchestrates phase 3 lung cancer win over Amgen and BMS
Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial.
Nick Paul Taylor
Jul 2, 2026 8:30am
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Dec 10, 2024 4:05pm
Merck's early KRAS data suggest combination-friendly safety
Oct 23, 2023 9:45am
Next round of KRAS drugs follow footsteps of Amgen and Mirati
May 4, 2023 6:00am
AACR: Lilly challenges Amgen, Mirati with early KRAS data
Apr 17, 2023 2:30pm
Sanofi sets Revolution back, sending lead asset to the docks
Dec 8, 2022 7:14am
